ArticleFrontiers in oncology2022

Early [18]FDG PET/CT scan predicts tumor response in head and neck squamous cell cancer patients treated with erlotinib adjusted per smoking status.

Mercedes Porosnicu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.